Healthy Volunteers
Conditions
Brief summary
The main aims of this study are to check for side effects from TAK-881 in healthy adults and to learn how much TAK-881 they can receive without getting side effects from it. During the study, participants will receive one infusion of TAK-881 under the skin (subcutaneous infusion) on Day 1 at a lower dose level followed by participants receiving one infusion of higher dose levels with ongoing safety monitored by the doctor to ensure optimal tolerability and safety. Participants will stay in the clinic for 4 days and will come back after 4 weeks. A follow up visit will take place 12 weeks after the TAK-881 infusion.
Interventions
BIOLOGICALTAK-881
Participants will receive subcutaneous infusion of TAK-881 on Day 1.
Sponsors
Takeda Development Center Americas, Inc.
Baxalta Innovations GmbH, now part of Shire
Takeda
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* An understanding, ability, and willingness to fully comply with study procedures and restrictions. * Ability to voluntarily provide written, signed, and dated (personally or via a legally-authorized representative) informed consent as applicable to participate in the study. * Age 19-50 years inclusive at the time of consent. The date of signature of the informed consent is defined as the beginning of the screening period. This inclusion criterion will only be assessed at the first screening visit. * Male, or non-pregnant, non-breastfeeding female who agrees to comply with any applicable contraceptive requirements of the protocol, or female of non-childbearing potential. * Must be considered healthy. Healthy as determined by the investigator on the basis of screening evaluations. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead electrocardiogram (ECG), hematology, blood chemistry, and urinalysis. * Body mass index (BMI) between 18.0 and 30.0 kilogram per square meter (kg/m\^2) inclusive.
Exclusion criteria
\- Any current or relevant history of medical (e.g., any hematological, hepatic, respiratory, cardiovascular, renal, or neurological) or psychiatric conditions, which by judgment of the investigator might compromise the safety of the participant or integrity of the study, interfere with the participants participation in the trial and compromise the trial objectives, or any condition that presents an undue risk from the IP or procedures. Note: Participants on stable dose of hormone replacements (e.g., thyroid hormone replacement) or oral contraceptives are permitted. * Clinically significant cardiac conditions including but not limited to uncontrolled hypertension, myocardial infarction, unstable coronary artery disease and clinically significant arrhythmias and conduction disorders. * Known or suspected intolerance or hypersensitivity to the IP(s), closely related compounds, or any of the stated ingredients (e.g., human immune globulin (IG), hyaluronidase, albumin). * Known history of hypersensitivity or severe allergic reactions (e.g., urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following administration of blood or blood components. * Known allergy to hyaluronidase of human (including recombinant human hyaluronidase) or animal origin (such as bee or wasp venom). * Significant illness, as judged by the investigator, within 30 days of the first dose of IP. * Known history of alcohol or other substance abuse within the last year. * Donation of blood within 60 days, or blood products (e.g., plasma or platelets) within 2 weeks prior receiving the first dose of IP. * Participants will be excluded if abnormal hematology, chemistry, and other laboratory values are greater than (\>)10% above the upper limit of normal (ULN) or \>10% below the lower limit of normal (LLN) except for liver function tests and absolute neutrophils. Participants will be excluded if any of the following laboratory parameters meet the criteria below: * Absolute neutrophil count less than (\<) 1.5\* 10\^9 cells/liter * Liver function: alanine aminotransferase (ALT) greater than or equal to (\>=) 1.5\* ULN, aspartate aminotransferase (AST) \>=1.5\* ULN, alkaline phosphatase (ALP) \>=1.5\* ULN, or total bilirubin \>=1.5 milligram per deciliter (mg/dL) * Participants will be excluded if any other laboratory values are outside the reference range and are clinically significant per investigator's judgment. * Participants who, within 30 days prior to the first dose of IP: * Have participated in another clinical study involving IG products within 12 months of screening. * Have used an IP (or 5 half-lives, whichever is longer). * Have been enrolled in a clinical study (including vaccine studies or has been vaccinated with approved product) that, in the investigator's opinion, may impact this study. Participants who have received any vaccine (including live attenuated vaccines and COVID-19 vaccines) during the last 30 days before dosing will be excluded. No live attenuated virus vaccines are allowed during the study until the end of the follow-up period. * Have had any substantial changes in eating habits, as assessed by the investigator. * Confirmed systolic blood pressure \>139 millimeter of mercury (mmHg) or \<89 mmHg and diastolic blood pressure \>89 mmHg or \<49 mmHg. * A positive screen for alcohol or drugs of abuse at screening or Day -1 (D-1). * A positive human immunodeficiency virus (HIV), hepatitis C virus (HCV), or ongoing/active hepatitis B infection at screening. Participants with immunity to hepatitis B from either active vaccination or from previous natural infection are eligible to participate in the study. * Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during confinement in the clinical research center (CRC). * Severe dermatitis or anatomical abnormality that would interfere with TAK-881 administration or endpoint assessments. Note: The skin at the administration site should not be covered by tattoos. * Current use of any herbal or homeopathic preparations is not permitted. * Unable or unwilling to discontinue antihistamines or medications with antihistamine properties, sedatives, anxiolytics, systemic steroids, or topical steroids or antibiotics on any area below the chest for a minimum of 48 hours prior to infusion visit and through 72 hours post infusion. * Current or relevant history of hypercoagulable conditions (e.g., Protein C, Protein S, and antithrombin III deficiency), thrombotic/thromboembolic events or venous thrombosis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site | Up to Day 4 | A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced or the infusion was not interrupted or stopped, due to any treatment-emergent adverse event (TEAE) related to TAK-881. Number of participants with tolerability events related to infusion of TAK-881 per infusion sites (1 and 2) were reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With TEAEs | From the start of study drug administration up to Week 13 | A TEAE was defined as any event emerged or manifested at or after the initiation of treatment with an Investigational product (IP) or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the IP or medicinal product. Any clinically significant treatment-emergent changes in clinical laboratory measurements and vital signs were recorded as TEAEs. Number of participants with TEAEs were reported. |
| Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20 | Baseline up to Week 13 | Positive binding ADA was defined as titer greater than or equal to (\>=) 1:160. Neutralizing antibodies were only tested if binding ADA titer was \>= 1:160. Number of participants with positive binding ADA and neutralizing antibodies to rHuPH20 were reported. |
| Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Day 1 up to Day 4 | The maximum tolerable infusion rate achieved referred to the administration of IGSC, 20% at progressively increasing infusion rates and was defined as the highest infusion rate achieved at which the infusion was tolerable (i.e., no stopping, interruption, or infusion rate reduction due to a TAK-881-related TEAE). The maximum tolerable infusion rate for Infusion Site 2 depended on the planned volume according to the stepwise infusion rate escalation regimen. Number of participants who achieved maximum tolerable infusion rate per infusion sites (1 and 2) for each infusion rate (30, 60, 120, 180, and 300 milliliter per hour \[mL/hour\]) were reported. |
| Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | At Day 1 | Total volume infused per infusion sites (1 and 2) for rHuPH20 and IGSC were reported. |
| Time to Deliver the Total Infused Volume Per Infusion Site | At Day 1 | Time to deliver (in minutes) the total infused volume was calculated as (stop date/time of IGSC 20% administration) - (start date/time of rHuPH20 administration). Time to deliver the total infused volume per infusion sites (1 and 2) were reported. |
Countries
United States
Participant flow
Recruitment details
This study was conducted at single center in the United States from 12 October 2021 to 12 April 2022.
Pre-assignment details
A total of 24 participants were enrolled and received the study treatment in this study.
Participants by arm
| Arm | Count |
|---|---|
| TAK-881 0.4 g/kg Warmed Participants received a single dose of TAK-881 comprised of 0.4 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and an rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period of 4 days. Participants were followed up to 12 (±1) weeks after the TAK-881 infusion. | 8 |
| TAK-881 1.0 g/kg Warmed Participants received a single dose of TAK-881 comprised of 1.0 g/kg (in-line warmed) IGSC, 20% at progressively increased infusion rates and an rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period of 4 days. Participants were followed up to 12 (±1) weeks after the TAK-881 infusion. | 8 |
| TAK-881 1.0 g/kg Un-warmed Participants received a single dose of TAK-881 comprised of 1.0 g/kg (un-warmed) IGSC, 20% at progressively increased infusion rates and an rHuPH20 dose of 80 U/g IgG on Day 1 of the study treatment period of 4 days. Participants were followed up to 12 (±1) weeks after the TAK-881 infusion. | 8 |
| Total | 24 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Withdrawal by Subject | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | TAK-881 0.4 g/kg Warmed | TAK-881 1.0 g/kg Warmed | TAK-881 1.0 g/kg Un-warmed | Total |
|---|---|---|---|---|
| Age, Continuous | 42.6 years STANDARD_DEVIATION 4.57 | 39.4 years STANDARD_DEVIATION 4.1 | 34.9 years STANDARD_DEVIATION 10.12 | 39.0 years STANDARD_DEVIATION 7.29 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 8 Participants | 7 Participants | 8 Participants | 23 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 8 Participants | 7 Participants | 8 Participants | 23 Participants |
| Sex: Female, Male Female | 5 Participants | 2 Participants | 4 Participants | 11 Participants |
| Sex: Female, Male Male | 3 Participants | 6 Participants | 4 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 8 | 0 / 8 |
| other Total, other adverse events | 8 / 8 | 8 / 8 | 8 / 8 |
| serious Total, serious adverse events | 0 / 8 | 0 / 8 | 0 / 8 |
Outcome results
Primary
Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site
A tolerability event was considered to have occurred if an infusion was tolerable. An infusion was considered tolerable if the infusion rate was not reduced or the infusion was not interrupted or stopped, due to any treatment-emergent adverse event (TEAE) related to TAK-881. Number of participants with tolerability events related to infusion of TAK-881 per infusion sites (1 and 2) were reported.
Time frame: Up to Day 4
Population: Safety set included all participants who received a partial or a full dose of TAK-881. Here, number analyzed signifies those participants who were evaluable for given categories of this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TAK-881 0.4 g/kg Warmed | Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site | Infusion Site 1 | 8 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site | Infusion Site 1 | 8 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site | Infusion Site 2 | 4 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site | Infusion Site 1 | 8 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants With Tolerability Events Related to Infusion of TAK-881 Per Infusion Site | Infusion Site 2 | 7 Participants |
Secondary
Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site
The maximum tolerable infusion rate achieved referred to the administration of IGSC, 20% at progressively increasing infusion rates and was defined as the highest infusion rate achieved at which the infusion was tolerable (i.e., no stopping, interruption, or infusion rate reduction due to a TAK-881-related TEAE). The maximum tolerable infusion rate for Infusion Site 2 depended on the planned volume according to the stepwise infusion rate escalation regimen. Number of participants who achieved maximum tolerable infusion rate per infusion sites (1 and 2) for each infusion rate (30, 60, 120, 180, and 300 milliliter per hour \[mL/hour\]) were reported.
Time frame: Day 1 up to Day 4
Population: Safety set included all participants who received a partial or a full dose of TAK-881. Here, number analyzed signifies those participants who were evaluable for specified categories of this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TAK-881 0.4 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 30 mL/hour | 0 Participants |
| TAK-881 0.4 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 60 mL/hour | 0 Participants |
| TAK-881 0.4 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 120 mL/hour | 0 Participants |
| TAK-881 0.4 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 180 mL/hour | 0 Participants |
| TAK-881 0.4 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 300 mL/hour | 8 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 60 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 120 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 300 mL/hour | 3 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 180 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 300 mL/hour | 8 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 30 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 60 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 120 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 30 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 180 mL/hour | 1 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 120 mL/hour | 1 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 180 mL/hour | 1 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 30 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 120 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 60 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 60 mL/hour | 2 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 180 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 2: 300 mL/hour | 3 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 30 mL/hour | 0 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants Who Achieved Maximum Tolerable Infusion Rate Per Infusion Site | Infusion Site 1: 300 mL/hour | 8 Participants |
Secondary
Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20
Positive binding ADA was defined as titer greater than or equal to (\>=) 1:160. Neutralizing antibodies were only tested if binding ADA titer was \>= 1:160. Number of participants with positive binding ADA and neutralizing antibodies to rHuPH20 were reported.
Time frame: Baseline up to Week 13
Population: Safety set included all participants who received a partial or a full dose of TAK-881. Here, number analyzed signifies those participants who were evaluable for specified categories of this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| TAK-881 0.4 g/kg Warmed | Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20 | Binding Antibodies | 0 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20 | Binding Antibodies | 0 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants With Positive Binding Anti-Drug Antibodies (ADA) and Neutralizing Antibodies to rHuPH20 | Binding Antibodies | 0 Participants |
Secondary
Number of Participants With TEAEs
A TEAE was defined as any event emerged or manifested at or after the initiation of treatment with an Investigational product (IP) or medicinal product or any existing event that worsened in either intensity or frequency following exposure to the IP or medicinal product. Any clinically significant treatment-emergent changes in clinical laboratory measurements and vital signs were recorded as TEAEs. Number of participants with TEAEs were reported.
Time frame: From the start of study drug administration up to Week 13
Population: Safety set included all participants who received a partial or a full dose of TAK-881.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| TAK-881 0.4 g/kg Warmed | Number of Participants With TEAEs | 8 Participants |
| TAK-881 1.0 g/kg Warmed | Number of Participants With TEAEs | 8 Participants |
| TAK-881 1.0 g/kg Un-warmed | Number of Participants With TEAEs | 8 Participants |
Secondary
Time to Deliver the Total Infused Volume Per Infusion Site
Time to deliver (in minutes) the total infused volume was calculated as (stop date/time of IGSC 20% administration) - (start date/time of rHuPH20 administration). Time to deliver the total infused volume per infusion sites (1 and 2) were reported.
Time frame: At Day 1
Population: Safety set included all participants who received a partial or a full dose of TAK-881. Here, number analyzed signifies those participants who were evaluable for specified categories of this outcome measure.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| TAK-881 0.4 g/kg Warmed | Time to Deliver the Total Infused Volume Per Infusion Site | Infusion Site 1 | 63.5 minute |
| TAK-881 1.0 g/kg Warmed | Time to Deliver the Total Infused Volume Per Infusion Site | Infusion Site 1 | 99.5 minute |
| TAK-881 1.0 g/kg Warmed | Time to Deliver the Total Infused Volume Per Infusion Site | Infusion Site 2 | 53.0 minute |
| TAK-881 1.0 g/kg Un-warmed | Time to Deliver the Total Infused Volume Per Infusion Site | Infusion Site 1 | 102.0 minute |
| TAK-881 1.0 g/kg Un-warmed | Time to Deliver the Total Infused Volume Per Infusion Site | Infusion Site 2 | 41.0 minute |
Secondary
Total Volume Infused Per Infusion Site for rHuPH20 and IGSC
Total volume infused per infusion sites (1 and 2) for rHuPH20 and IGSC were reported.
Time frame: At Day 1
Population: Safety set included all participants who received a partial or a full dose of TAK-881. Here, number analyzed signifies those participants who were evaluable for specified categories of this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| TAK-881 0.4 g/kg Warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | rHuPH20: Infusion Site 1 | 14.3 milliliter (mL) | Standard Deviation 1.28 |
| TAK-881 0.4 g/kg Warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | IGSC 20%: Infusion Site 1 | 141.3 milliliter (mL) | Standard Deviation 13.3 |
| TAK-881 1.0 g/kg Warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | rHuPH20: Infusion Site 1 | 29.3 milliliter (mL) | Standard Deviation 1.39 |
| TAK-881 1.0 g/kg Warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | rHuPH20: Infusion Site 2 | 10.0 milliliter (mL) | Standard Deviation 5.16 |
| TAK-881 1.0 g/kg Warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | IGSC 20%: Infusion Site 1 | 291.3 milliliter (mL) | Standard Deviation 14.33 |
| TAK-881 1.0 g/kg Warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | IGSC 20%: Infusion Site 2 | 97.5 milliliter (mL) | Standard Deviation 51.72 |
| TAK-881 1.0 g/kg Un-warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | rHuPH20: Infusion Site 1 | 29.4 milliliter (mL) | Standard Deviation 1.77 |
| TAK-881 1.0 g/kg Un-warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | IGSC 20%: Infusion Site 1 | 293.8 milliliter (mL) | Standard Deviation 17.68 |
| TAK-881 1.0 g/kg Un-warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | rHuPH20: Infusion Site 2 | 7.3 milliliter (mL) | Standard Deviation 6.16 |
| TAK-881 1.0 g/kg Un-warmed | Total Volume Infused Per Infusion Site for rHuPH20 and IGSC | IGSC 20%: Infusion Site 2 | 70.0 milliliter (mL) | Standard Deviation 61.64 |